Efficacy of Low Dose Chemoprophylaxis for Coccidioidomycosis Infection in Liver Transplant Recipients
Author
Habib, ShahidEl Ramahi, Razan A
Rosen, Scott
Farran, Sumaya
Shubeilat, Jamilah
Walker, Courtney
Casal, Mariana
Zangeneh, Tirdad
Affiliation
Univ Arizona, Banner Univ, Med CtrIssue Date
2019-06
Metadata
Show full item recordPublisher
ELMER PRESS INCCitation
Habib, S., El Ramahi, R. A., Rosen, S., Farran, S., Shubeilat, J., Walker, C., ... & Zangeneh, T. (2019). Efficacy of Low Dose Chemoprophylaxis for Coccidioidomycosis Infection in Liver Transplant Recipients. Gastroenterology Research, 12(3), 148.Journal
GASTROENTEROLOGY RESEARCHRights
© The authors. This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background: Coccidioidomycosis (CM) infections among transplant recipients result in significant morbidity and mortality. The goal of our study was to establish the efficacy of low dose (LD) versus standard dose (LD, 50 mg daily) fluconazole in preventing CM infection. Methods: This was a retrospective study utilizing electronic medical records of liver transplant recipients at the University of Arizona. The primary end point was post-transplant CM status, such as infection, complications and survival. Results: We detected a statistically significant correlation between positive pre-transplant status and positive post-transplant status (hazards ratio: 8.25 (95% confidence interval: 1.028 - 66.192)). There was a trend towards improved survival in patients who had a positive post-transplant CM status in the SD group versus LD group (90.9% versus 81.3%), although not statistically significant. Conclusion: The risk of CM infection among transplant recipients in the absence of prophylaxis is associated with high morbidity and mortality. We currently use SD fluconazole as universal prophylaxis in all transplant recipients despite not establishing statistical significance between LD and SD. We believe that the survival trend detected may have not reached statistical significance due to low power impact. Since the standardization of SD prophylaxis at our institution, we have not diagnosed further new post-transplant CM infections.Note
Open access journalISSN
1918-2805EISSN
1918-2813PubMed ID
31236156DOI
10.14740/gr1182Version
Final published versionae974a485f413a2113503eed53cd6c53
10.14740/gr1182
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © The authors. This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License.
Related articles
- Universal fungal prophylaxis and risk of coccidioidomycosis in liver transplant recipients living in an endemic area.
- Authors: Kahn A, Carey EJ, Blair JE
- Issue date: 2015 Mar
- Safety of fluconazole in kidney transplant recipients for prevention of coccidioidomycosis.
- Authors: Reddy L, Thompson Iii GR, Tuznik N, Zolfaghari TA, Dray JV, Ames J, Ho D, Crabtree S, Fine J, Wilson MD, Alnimri M, Cohen SH, Koff A
- Issue date: 2024 Mar 7
- Universal azole prophylaxis for prevention of coccidioidomycosis among lung transplant recipients transferring care to a center within a highly endemic region.
- Authors: Goodlet KJ, Garcia R, Nailor MD
- Issue date: 2025 Jan-Feb
- Single-center experience of antifungal prophylaxis for coccidioidomycosis in heart transplant recipients within an endemic area.
- Authors: Lohrmann GM, Vucicevic D, Lawrence R, Steidley DE, Scott RL, Kusne S, Blair JE
- Issue date: 2017 Oct
- Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area.
- Authors: Blair JE, Douglas DD, Mulligan DC
- Issue date: 2003 Mar